Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Traws Pharma, Inc. Director's Dealing 2022

Dec 20, 2022

35199_dirs_2022-12-19_04d75275-5d3a-45cf-8fe6-e70a80f10d7a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2022-12-15

Reporting Person: Atadja Peter (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-12-15 Stock Option (right to purchase) $0.71 A 100000 Acquired 2032-12-15 Common Stock (100000) Direct

Footnotes

F1: These options vest in 3 installments on the anniversary of the grant date: 33% on the first anniversary, 33% on the second anniversary and 34% on the third anniversary.